title: Moderate doses of EPA and DHA from re-esterified triacylglycerols but not from ethyl-esters lower fasting serum triacylglycerols in statin-treated dyslipidemic subjects: Results from a six month randomized controlled trial.
abstract: Recently, in a supplementation study over six months, it has been demonstrated that re-esterified omega-3 fatty acid triacylglycerols (n3-FA-rTAGs) led to a higher increase in omega-3-index compared to identical doses of n3-FA ethyl-esters (n3-FA-EEs), suggesting a better long-term bioavailability. The aim of this study was to examine whether differences occur between the two forms in affecting fasting serum lipid levels. 150 dyslipidemic statin-treated participants were randomized to corn oil as a placebo or fish oil either as rTAG or EE in identical doses (1.01g EPA+0.67g DHA). No changes in total cholesterol, HDL or LDL levels were observed. In the rTAG-group, but not in the EE-group, fasting serum TAG levels were significantly reduced from baseline after three and six months. There was no significant difference between the two n3-FA-groups. However, serum TAG levels were significantly lowered after six months in the rTAG-group compared to the placebo-group in contrast to the EE-group.
authors.affiliation: Institute of Food Science and Human Nutrition, Leibniz University Hannover, Am Kleinen Felde 30, 30167 Hanover, Germany. schuchardt@nutrition.uni-hannover.de
authors.forename: J P
authors.initials: JP
authors.lastname: Schuchardt
authors.forename: J
authors.initials: J
authors.lastname: Neubronner
authors.forename: G
authors.initials: G
authors.lastname: Kressel
authors.forename: M
authors.initials: M
authors.lastname: Merkel
authors.forename: C
authors.initials: C
authors.lastname: von Schacky
authors.forename: A
authors.initials: A
authors.lastname: Hahn
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D001682:Biological Availability; D004281:Docosahexaenoic Acids / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004311:Double-Blind Method; D050171:Dyslipidemias / Q000188:drug therapy*; D015118:Eicosapentaenoic Acid / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D014280:Triglycerides; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid